MedTrace Logo

Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis Patients

NCT01659593 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2016-03-08

No results posted yet for this study

Summary

Cognitive disorders are well-known in multiple sclerosis (MS), even in earlier stages of the disease. They effect personal life. Their management may be overlooked. The evidence-based program proposes exercises to both stimulate preserved functions and develop new abilities compensating for cognitive disabilities.

Aim of the study is to evaluate the efficiency of the remedial program (PROCOG-SEP) designed for MS patients, compared to an interactive discussion program(DISINT) 140 multiple sclerosis patients will be randomly assigned in one the program for 13 sessions over a 6-month period.

Main outcome criteria is evolution of SRT-LIST before and after program.

Conditions

Interventions

OTHER

procog

3 to 5 people group program

OTHER

Placebo

Sponsors & Collaborators

  • University Hospital, Strasbourg, France

    collaborator OTHER

  • Centre Hospitalier Universitaire Dijon

    collaborator OTHER

  • Centre Hospitalier Universitaire de Besancon

    collaborator OTHER

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Marc DEBOUVERIE, Professor · CHU NANCY

  • Eric BERGER, MD · CHU DE BESANCON

  • Thibaut MOREAU, Professor · Centre Hospitalier Universitaire Dijon

  • Jérôme de Sèze, Professor · CHU de STRASBOURG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2016-09-30
Completion
2018-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01659593 on ClinicalTrials.gov